Separately, Zacks Investment Research cut shares of Cidara Therapeutics from a buy rating to a hold rating in a research report on Friday, January 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Cidara Therapeutics presently has a consensus rating of Buy and an average target price of $13.56.
Shares of Cidara Therapeutics stock opened at $6.00 on Monday. The company has a quick ratio of 6.43, a current ratio of 6.43 and a debt-to-equity ratio of 0.12. Cidara Therapeutics has a 1 year low of $5.60 and a 1 year high of $8.80.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Prosight Management LP bought a new stake in Cidara Therapeutics during the fourth quarter valued at $11,206,000. Broadfin Capital LLC boosted its position in shares of Cidara Therapeutics by 4.5% during the 4th quarter. Broadfin Capital LLC now owns 857,397 shares of the biotechnology company’s stock worth $5,830,000 after purchasing an additional 36,994 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Cidara Therapeutics by 26.2% during the 4th quarter. Renaissance Technologies LLC now owns 179,300 shares of the biotechnology company’s stock worth $1,219,000 after purchasing an additional 37,197 shares in the last quarter. Eversept Partners LLC bought a new position in shares of Cidara Therapeutics during the 4th quarter worth about $340,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Cidara Therapeutics by 77.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 18,001 shares in the last quarter. 71.87% of the stock is currently owned by institutional investors and hedge funds.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.